PSCA

Summary

PSCA (prostate stem cell antigen, HGNC:9500) is a protein-coding gene on chromosome 8q24.3, encoding Prostate stem cell antigen (O43653). May be involved in the regulation of cell proliferation.

This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. In addition to being highly expressed in the prostate it is also expressed in the bladder, placenta, colon, kidney, and stomach. This gene is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. This gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 8000 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 28 total
• Druggable target: yes
• MANE Select transcript: NM_005672

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9500
Approved symbol	PSCA
Name	prostate stem cell antigen
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	lncPSCA
Ensembl gene	ENSG00000167653
Ensembl biotype	protein_coding
OMIM	602470
Entrez	8000

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000301258, ENST00000505305, ENST00000510969, ENST00000513264, ENST00000918921, ENST00000966863

RefSeq mRNA: 1 — MANE Select: NM_005672 NM_005672

CCDS: CCDS47925

Canonical transcript exons

ENST00000301258 — 3 exons

Exon	Start	End
ENSE00001115318	142681921	142682725
ENSE00002074308	142680495	142680563
ENSE00003610878	142681327	142681434

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 99.50.

FANTOM5 (CAGE): breadth broad, TPM avg 8.6594 / max 2413.6191, expressed in 852 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
91354	6.8540	248
91350	0.9044	396
91349	0.5349	294
91352	0.1429	51
91351	0.1353	47
91353	0.0879	36

Top tissues by expression

154 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.50	gold quality
mucosa of stomach	UBERON:0001199	98.45	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.15	gold quality
esophagus mucosa	UBERON:0002469	94.79	gold quality
epithelium of bronchus	UBERON:0002031	93.90	gold quality
body of stomach	UBERON:0001161	93.46	gold quality
stomach	UBERON:0000945	92.76	gold quality
urinary bladder	UBERON:0001255	90.67	gold quality
prostate gland	UBERON:0002367	90.53	gold quality
vagina	UBERON:0000996	88.28	gold quality
trachea	UBERON:0003126	86.86	gold quality
fundus of stomach	UBERON:0001160	86.42	gold quality
skin of leg	UBERON:0001511	79.75	gold quality
right lung	UBERON:0002167	79.69	gold quality
gall bladder	UBERON:0002110	79.25	gold quality
zone of skin	UBERON:0000014	78.69	gold quality
skin of abdomen	UBERON:0001416	77.83	gold quality
esophagus	UBERON:0001043	77.53	gold quality
minor salivary gland	UBERON:0001830	75.80	gold quality
saliva-secreting gland	UBERON:0001044	75.41	gold quality
tonsil	UBERON:0002372	74.84	gold quality
placenta	UBERON:0001987	73.95	gold quality
ectocervix	UBERON:0012249	73.02	gold quality
right uterine tube	UBERON:0001302	72.56	gold quality
duodenum	UBERON:0002114	72.04	gold quality
uterine cervix	UBERON:0000002	70.63	gold quality
metanephros cortex	UBERON:0010533	70.32	gold quality
thymus	UBERON:0002370	69.47	silver quality
layer of synovial tissue	UBERON:0007616	69.32	gold quality
endocervix	UBERON:0000458	69.31	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	57.20
E-HCAD-10	yes	16.38
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, YY1

miRNA regulators (miRDB)

21 targeting PSCA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-6748-3P	97.20	65.66	836
HSA-MIR-6508-3P	96.73	65.48	576
HSA-MIR-552-3P	96.68	64.12	1026
HSA-MIR-6823-5P	96.26	65.69	919

Literature-anchored findings (GeneRIF, showing 40)

• This transgenic system helps define the range of cellular changes associated with altered expression of PSCA, shows that transcriptional control is a major component regulating PSCA levels. (PMID:11752398)
• Here we describe the identification of a compact cell-specific and androgen-responsive enhancer between 2.7 and 3 kb upstream of the transcription start site. The enhancer functions autonomously when positioned immediately adjacent to a minimal promoter. (PMID:12351697)
• PSCA is expressed in an intermediate subpopulation of PrEC in transition from a basal to a terminally differentiated secretory phenotype (PMID:12496358)
• Data suggest that PSCA is a promising tumor marker and potential therapeutic target for patients with metastatic prostate cancer. (PMID:15814638)
• Significantly higher prostate stem cell antigen copy number was associated with pancreatic cancer (PMID:16957968)
• The chimeric alpha-PSCA-beta2/CD3zeta-TCR might now be used for arming human cytotoxic T-cells for further studies towards a clinical treatment of prostate cancer. (PMID:17492652)
• data identify prostate stem cell antigen(PSCA) mRNA in initial prostatic intraepithelial neoplasia (PIN) as a significant predictor of subsequent prostate cancer (PMID:17503471)
• Increased levels of IgG antibodies against the prostate stem cell antigen in the plasma is associated with pancreatic cancer (PMID:17549363)
• Result shows PSCA contains the cleavage site of the ER signal peptidase and the resulting cleavage products fail to bind to HLA-A(*)0201 and are not recognized by T lymphocytes. (PMID:17853904)
• This prospective study identifies PSCA mRNA in BPH as a significant predictor of cancer development after TURP (PMID:18076024)
• Overexpression of prostate stem cell antigen (PSCA) is associated with development of gestational trophoblastic neoplasia in hydatidiform mole. (PMID:18184265)
• combination of prostate stem cell antigen enhancer and uroplakin II promoter is feasible in constructing bladder cancer-specific vectors (PMID:18440837)
• Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer (PMID:18488030)
• the expression of PSCA correlates with relevant clinical benchmarks, such as Gleason score and metastasis. (PMID:18838214)
• The expressions of PSCA and Claudin-4 are upregulated in the pancreatic carcinomas. (PMID:19180924)
• Prostate stem cell antigen and prostate-specific membrane antigen are both highly expressed in lymph node and bone metastases of prostate cancer. (PMID:19343734)
• This prospective study identifies PSCA mRNA in preoperatively negative prostatic biopsies as a significant predictor of subsequent cancer after TURP. (PMID:19462463)
• Genetic variations in prostate stem cell antigen is associated with gastric cancer. (PMID:19554573)
• Prostate stem cell antigen polymorphisms are associated with stomach cancer. (PMID:19582881)
• Genetic variation in PSCA confers susceptibility to urinary bladder cancer. (PMID:19648920)
• Suggest that PSCA is a marker associated with neoplastic transformation of prostate cells, both in cystoprostatectomies with incidental prostate carcinoma and radical prostatectomies. (PMID:19822092)
• The expression of PSCA can be related to the development of pancreatic cancer, but not to the clinicopathological factors of the tumor. (PMID:19861285)
• rs2294008 polymorphism of PSCA gene may play a role in bladder cancer carcinogenesis. (PMID:20083643)
• Prostate stem cell antigen is highly expressed in non-small cell lung cancer and may be functionally important for this fatal disease. (PMID:20085909)
• PSCA gene polymorphisms may be associated with gastric cancer in Tibetans. (PMID:20230293)
• Correlation between the level of PSCA expression and tumor growth and suggest a role of PSCA in counteracting the natural immune response.in bladder cancer. (PMID:20374648)
• REVIEW: PSCA seems to be a Jekyll and Hyde molecule that plays differential roles, tumor promoting or suppressing, depending on the cellular context. (PMID:20501618)
• We report the first analysis of PSCA, PIWIL1, and TBX2 expression in EAC. Our findings suggest that PSCA and TBX2 might be candidate targets for cancer therapy. (PMID:20502058)
• prostate stem cell antigen is a marker associated with neoplastic transformation of prostate cells (PMID:20955382)
• Genetic variant in PSCA is associated with diffuse-type gastric cancer. (PMID:21064099)
• The rs2294008 polymorphism in prostate stem cell antigen increases the risk of noncardia gastric cancer and its precursors in white individuals but protects against proximal cancers. (PMID:21070776)
• Data show that the T allele of PSCA rs2294008 is associated with increased risk of gastric cancer. (PMID:21268123)
• Data indicate that RNA silencing of PSCA can inhibit the proliferation and invasiveness properties of prostate cancer PC-3M cells, which may provide a promising therapeutic strategy for prostate cancer. (PMID:21429770)
• Men with the rs1045531 AA genotype of PSCA were at higher risk for prostate cancer. On haplotype analysis CCCAGGTACGG and CGA haplotype carriers showed a significant association with prostate cancer risk (PMID:21497359)
• prostate stem cell antigen is a novel glioma-associated antigen (PMID:21503583)
• This study showed that rs2294008 in the PSCA gene was associated with increased risks of gastric cancer in a Korean population, suggests that rs2294008 might play an important role in gastric carcinogenesis. (PMID:21538581)
• Data indicate that PSA, PSMA, hK2, PSCA, DD3, and their combinations, combined analysis of PSA and/or hK2 expression in pelvic lymph nodes could predict biochemical recurrence free survival (BRFS) following radical prostatectomy (RP). (PMID:21600799)
• results confirm the association between variation in the promoter region of PSCA and GC risk in Caucasians and also indicate that the rs2294008 variant is a similar risk factor for both the diffuse and intestinal-types of GC. (PMID:21681742)
• Integrin alpha(nu) beta(3), NTRS1 and PSCA mRNA expression increased with tumorigenic potential, but mRNA expression levels for these proteins do not translate directly to equivalent expression levels of membrane bound protein. (PMID:21748756)
• PSCA might play an important role in lymph node metastasis in PSCA might play an important role in lymph node metastasis in the breast. Expression of PSCA was correlated with lymph nodes metastasis. (PMID:21914346)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Psca	ENSMUSG00000022598
rattus_norvegicus	Psca	ENSRNOG00000061376

Paralogs (2): LY6E (ENSG00000160932), GPIHBP1 (ENSG00000277494)

Protein

Protein identifiers

Prostate stem cell antigen — O43653 (reviewed: O43653)

All UniProt accessions (2): O43653, H0YAA6

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the regulation of cell proliferation. Has a cell-proliferation inhibition activity in vitro. May act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro inhibits nicotine-induced signaling probably implicating alpha-3:beta-2- or alpha-7-containing nAChRs.

Subunit / interactions. Interacts with CHRNA4.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in prostate (basal, secretory and neuroendocrine epithelium cells). Also found in bladder (transitional epithelium), placenta (trophoblasts), stomach (neuroendocrine cells), colon (neuroendocrine cells) and kidney (collecting ducts). Overexpressed in prostate cancers and expression is correlated with tumor stage, grade and androgen-independence. Highly expressed in prostate cancer bone metastases. Expressed in gastric epithelial cells, mainly in the isthmus (at protein level). Not detected in normal intestinal epithelium (at protein level). Expressed in brain cortex; expression is significantly increased in the front cortex of Alzheimer disease patients.

Post-translational modifications. N-glycosylated.

Induction. Down-regulated in gastric cancer cells.

Polymorphism. Genetic variations in PSCA may influence susceptibility to some cancers. A polymorphism gives rise to an upstream methionine which produces a longer protein of 123 residues associated with various cancers including diffuse-type gastric cancer and urinary bladder cancer.

RefSeq proteins (1): NP_005663* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016054	LY6_UPA_recep-like	Domain
IPR035076	Toxin/TOLIP	Domain
IPR045860	Snake_toxin-like_sf	Homologous_superfamily
IPR051110	Ly-6/neurotoxin-like_GPI-ap	Family

Pfam: PF00087

UniProt features (14 total): disulfide bond 5, sequence variant 2, signal peptide 1, chain 1, sequence conflict 1, propeptide 1, domain 1, lipid moiety-binding region 1, glycosylation site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9U9N	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43653-F1	81.93	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 83

Disulfide bonds (5): 78–83, 14–39, 17–26, 32–57, 61–77

Glycosylation sites (1): 31

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins

MSigDB gene sets: 149 (showing top): GOBP_NEGATIVE_REGULATION_OF_ERK1_AND_ERK2_CASCADE, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_NEGATIVE_REGULATION_OF_MAPK_CASCADE, GOBP_CELL_CELL_SIGNALING, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, BROWNE_HCMV_INFECTION_48HR_DN, MODULE_379, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_SYNAPTIC_SIGNALING, GOBP_RESPONSE_TO_ACETYLCHOLINE, MODULE_6, GOBP_REGULATION_OF_NEUROTRANSMITTER_RECEPTOR_ACTIVITY

GO Biological Process (3): negative regulation of ERK1 and ERK2 cascade (GO:0070373), acetylcholine receptor signaling pathway (GO:0095500), regulation of neurotransmitter receptor activity (GO:0099601)

GO Molecular Function (2): acetylcholine receptor regulator activity (GO:0030548), acetylcholine receptor binding (GO:0033130)

GO Cellular Component (6): extracellular region (GO:0005576), plasma membrane (GO:0005886), synapse (GO:0045202), extracellular exosome (GO:0070062), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
acetylcholine receptor activity	2
membrane	2
negative regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
postsynaptic signal transduction	1
cellular response to acetylcholine	1
regulation of signaling receptor activity	1
neurotransmitter receptor activity	1
neurotransmitter receptor regulator activity	1
signaling receptor binding	1
cell periphery	1
cell junction	1
extracellular vesicle	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

1266 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PSCA	FOLH1	Q04609	910
PSCA	LY6E	Q16553	896
PSCA	KLK3	P07288	777
PSCA	STEAP1	Q9UHE8	751
PSCA	MUC6	Q6W4X9	719
PSCA	MSLN	Q13421	703
PSCA	NAT1	P18440	673
PSCA	MUC1	P13931	665
PSCA	CYP2E1	P05181	644
PSCA	LYNX1	P0DP58	605
PSCA	JRK	O75564	602
PSCA	CD247	P20963	577
PSCA	KLF6	Q99612	572
PSCA	TYROBP	O43914	561
PSCA	SLURP1	P55000	551

IntAct

7 interactions, top by confidence:

A	B	Type	Score
PSCA	ITGA6	psi-mi:“MI:0914”(association)	0.530
PSCA	CHRNA4	psi-mi:“MI:0915”(physical association)	0.400
ECE1	PSCA	psi-mi:“MI:0915”(physical association)	0.370
TEX101	GGT3P	psi-mi:“MI:0914”(association)	0.350
PSCA	METTL15	psi-mi:“MI:0914”(association)	0.350
PSCA	GPAA1	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: B3MFC2, B3NSF6, B4QBL6, B5A5T4, B5E022, D3ZTT2, D4A6L0, H3BQJ8, O43653, P12645, P19438, P22444, P23352, P46657, P49002, P50555, P57096, P58658, P58659, Q16553, Q1RMB5, Q28216, Q32LD3, Q505J3, Q568T5, Q5R510, Q5T848, Q66IA6, Q68US5, Q6UWL2, Q6UWN0, Q6UX15, Q6WN34, Q80XH4, Q86Y78, Q8BHE5, Q8BPP5, Q8BVP6, Q8C351, Q8C419

Diamond homologs: O43653, P0DP58, P57096, Q16553, Q6UXB3, Q90986, P0DP60, P0DP62, Q1RMQ4, Q5IS42, Q5IS87, Q64253, Q9DD23, A0JNB3, O94772, P05533, Q4R5M8, Q9WUC3, P0DP57, P0DP61, P55000, Q9Z0K7, A0A346CIB2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

431 predictions. Top by Δscore:

Variant	Effect	Δscore
8:142681324:CA:C	acceptor_loss	1.0000
8:142681435:G:GG	donor_gain	1.0000
8:142681461:GCC:G	donor_gain	1.0000
8:142680559:GCCAG:G	donor_gain	0.9900
8:142680561:CAGG:C	donor_loss	0.9900
8:142680562:AGG:A	donor_loss	0.9900
8:142680563:GGTGA:G	donor_loss	0.9900
8:142680564:G:GA	donor_loss	0.9900
8:142681325:A:AG	acceptor_gain	0.9900
8:142681325:AG:A	acceptor_gain	0.9900
8:142681326:G:GT	acceptor_gain	0.9900
8:142681326:GG:G	acceptor_gain	0.9900
8:142681326:GGC:G	acceptor_gain	0.9900
8:142681326:GGCA:G	acceptor_gain	0.9900
8:142681326:GGCAC:G	acceptor_gain	0.9900
8:142681409:G:T	donor_gain	0.9900
8:142681432:TCC:T	donor_gain	0.9900
8:142681409:G:GT	donor_gain	0.9800
8:142681433:CC:C	donor_gain	0.9800
8:142681915:CCCCA:C	acceptor_loss	0.9800
8:142681918:CAG:C	acceptor_loss	0.9800
8:142681919:A:G	acceptor_loss	0.9800
8:142681319:C:G	acceptor_gain	0.9600
8:142681430:CATCC:C	donor_gain	0.9600
8:142681433:CCGTG:C	donor_loss	0.9600
8:142681434:CG:C	donor_loss	0.9600
8:142681436:TGA:T	donor_loss	0.9600
8:142681437:G:GA	donor_loss	0.9600
8:142681438:A:AA	donor_loss	0.9600
8:142681439:G:A	donor_loss	0.9600

AlphaMissense

728 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:142681951:A:T	K55I	0.996
8:142681952:A:C	K55N	0.995
8:142681952:A:T	K55N	0.995
8:142682039:C:A	N84K	0.977
8:142682039:C:G	N84K	0.977
8:142681341:T:A	C14S	0.974
8:142681342:G:C	C14S	0.974
8:142681425:G:C	A42P	0.974
8:142681951:A:C	K55T	0.974
8:142682034:T:A	C83S	0.973
8:142682035:G:C	C83S	0.973
8:142681953:G:T	G56C	0.971
8:142681956:T:A	C57S	0.971
8:142681957:G:C	C57S	0.971
8:142681377:T:A	C26S	0.966
8:142681378:G:C	C26S	0.966
8:142681379:C:G	C26W	0.966
8:142681416:T:A	C39S	0.963
8:142681417:G:C	C39S	0.963
8:142681351:G:A	C17Y	0.961
8:142681418:C:G	C39W	0.961
8:142681950:A:G	K55E	0.960
8:142681350:T:A	C17S	0.958
8:142681351:G:C	C17S	0.958
8:142682035:G:A	C83Y	0.957
8:142682038:A:T	N84I	0.957
8:142681968:T:A	C61S	0.954
8:142681969:G:C	C61S	0.954
8:142681377:T:C	C26R	0.951
8:142681343:C:G	C14W	0.950

dbSNP variants (sampled 300 via entrez): RS1000432315 (8:142669360 C>A,T), RS1000484877 (8:142669533 G>A,C), RS1000816882 (8:142668456 T>C), RS1000893130 (8:142674397 C>A), RS1001018207 (8:142679937 G>A), RS1001241839 (8:142674219 T>C), RS1001442316 (8:142670742 T>C), RS1001617237 (8:142676733 T>C), RS1001843625 (8:142675348 T>A), RS1002359563 (8:142675043 C>T), RS1002628374 (8:142677807 G>A), RS1003102228 (8:142682996 A>C), RS1003679885 (8:142672558 A>C), RS1004287517 (8:142669292 G>A), RS1004794190 (8:142673620 G>A,T)

Disease associations

OMIM: gene MIM:602470 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000454_1	Bladder cancer	2.000000e-10
GCST000842_8	Bladder cancer	4.000000e-11
GCST001433_2	Duodenal ulcer	2.000000e-33
GCST002240_6	Bladder cancer	3.000000e-15
GCST002990_7	Gastric adenocarcinoma (histologically verified)	1.000000e-06
GCST002992_7	Gastric cancer	2.000000e-07
GCST003218_4	Non-cardia gastric cancer	6.000000e-11
GCST004075_16	Vertical cup-disc ratio	3.000000e-06
GCST004075_17	Vertical cup-disc ratio	5.000000e-09
GCST005012_24	Urinary tract infection frequency	3.000000e-10
GCST008062_37	Blood urea nitrogen levels	5.000000e-09
GCST008712_4	Pepsinogen I/II ratio	4.000000e-27
GCST008713_1	Severe gastric atrophy	2.000000e-13
GCST008714_1	Gastric atrophy	4.000000e-11
GCST009462_99	Optic disc size	5.000000e-08
GCST009872_2	Bladder cancer	5.000000e-06
GCST010956_1	Gastric cancer	2.000000e-13
GCST011769_17	Schizophrenia	5.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006939	cup-to-disc ratio measurement
EFO:0010149	pepsinogen I/II ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712961 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment, increases expression	5
bisphenol A	decreases expression, increases expression	3
sodium arsenite	increases expression, decreases expression	3
Benzo(a)pyrene	affects methylation, decreases expression	3
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, increases reaction, decreases expression	3
Cadmium Chloride	decreases expression, increases expression	3
Air Pollutants	increases abundance, affects expression, decreases expression	2
Smoke	decreases expression, increases expression	2
Luteolin	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects expression	2
aristolochic acid I	increases expression	1
bisphenol F	decreases expression	1
propionaldehyde	increases expression	1
kaempferol	decreases expression	1
sodium arsenate	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
arsenite	decreases methylation	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
myricetin	decreases expression	1
chrysin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
acyline	decreases expression	1
bisphenol B	decreases expression	1
abrine	increases expression	1
4-OH-2’,3,3’,4’,5’-pentachlorobiphenyl	decreases reaction, increases expression	1
bisphenol Z	decreases expression	1
bisphenol S	decreases expression	1
bisphenol AF	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2CC	Abcam HeLa PSCA KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.